The goal of this trial was to see how effective three months of oral mifepristone was at reducing the severity of symptoms and uterine and fibroid volume.
Methods: This was a prospective study undertaken in the Obstetrics & Gynecology department at Prathima Institute of Medical Sciences in Karimnagar, Telangana. Fifty symptomatic fibroids patients were given 25 mg of mifepristone daily for three months, and baseline data on Hb value, PBAC score, VAS (visual analogue scale), uterine volume, and fibroids volume were compared to those recorded at the end of the first month, third month, and three months after stopping mifepristone.
When compared to the pre-treatment value, Mifepristone treatment reduced mean PBAC score to 95% after one month, 98 percent after three months, and 58 percent after six months. After one month, 72 percent after three months, and 47 percent after three months of drug discontinuation, the mean VAS score was lowered to 67 percent, 72 percent after three months, and 47 percent after three months of drug discontinuation to pre-treatment value. In post-treatment follow-up patients, mean uterine volume was reduced by 24% after one month, 44% after three months, and 35% after six months when compared to pre-treatment values. In post-treatment follow-up patients, mean baseline fibroid volume was reduced by 25% after one month, 54% after three months, and 40% after six months. All of these measures increased slightly after quitting mifepristone, but they were still much lower than their baseline values. At the end of the third month of treatment, haemoglobin had increased by 2.12 gm/Dl from baseline, but had slightly reduced when compared to levels from the previous month. The baseline endometrium thickness was 7.4 mm, which grew to 8.24 mm after 3 months of treatment before returning to the baseline value, indicating that endometrial thickness was temporary throughout treatment. After treatment, 12 percent of patients became amenorrhoeic, however menstruation was restarted in 32.78 percent of post-treatment follow-up patients. During the research, there were only a few minor adverse effects.
Conclusion: A three-month course of low-dose oral Mifepristone 25 mg reduced menorrhagia, backache, dysmenorrhoea, and other related symptoms, reduced uterine and fibroid volume, and increased haemoglobin levels with little side effects.Author(S) Details
Alla Satyanarayana Reddy
Department of Obstetrics & Gynaecology, Vinayaka Mission’s Research Foundation (DU), Vinayaka Mission’s Medical College, Karaikal, India.
Aruna Giri
Vinayaka Mission’s Research Foundation (DU), Salem, India.
View Book:- https://stm.bookpi.org/RDMMR-V12/article/view/4676
No comments:
Post a Comment